KITOV PHARMA LT/S (NASDAQ:KTOV) shares were up 2.1% during trading on Tuesday . The stock traded as high as $0.80 and last traded at $0.79, approximately 23,278 shares traded hands during trading. A decline of 80% from the average daily volume of 115,971 shares. The stock had previously closed at $0.77.

Several research analysts have commented on KTOV shares. Zacks Investment Research upgraded KITOV PHARMA LT/S from a “sell” rating to a “hold” rating in a report on Tuesday, May 14th. ValuEngine upgraded KITOV PHARMA LT/S from a “sell” rating to a “hold” rating in a report on Monday, May 20th.

The stock has a fifty day simple moving average of $0.91. The stock has a market cap of $12.45 million, a P/E ratio of 2.03 and a beta of 3.72.

A hedge fund recently raised its stake in KITOV PHARMA LT/S stock. Virtu Financial LLC lifted its position in shares of KITOV PHARMA LT/S (NASDAQ:KTOV) by 70.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,898 shares of the company’s stock after purchasing an additional 16,069 shares during the quarter. Virtu Financial LLC owned about 0.25% of KITOV PHARMA LT/S worth $47,000 as of its most recent filing with the Securities & Exchange Commission. 0.63% of the stock is owned by institutional investors and hedge funds.


Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.

Featured Story: Sell-Side Analysts

Receive News & Ratings for KITOV PHARMA LT/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KITOV PHARMA LT/S and related companies with's FREE daily email newsletter.